Literature DB >> 11539926

Transmembrane transport of peptide type compounds: prospects for oral delivery.

E Lipka1, J Crison, G L Amidon.   

Abstract

Synthesis and delivery of potential therapeutic peptides and peptidomimetic compounds has been the focus of intense research over the last 10 years. While it is widely recognized that numerous limitations apply to oral delivery of peptides, some of the limiting factors have been addressed and their mechanisms elucidated, which has lead to promising strategies. This article will briefly summarize the challenges, results and current approaches of oral peptide delivery and give some insight on future strategies. The barriers determining peptide bioavailability after oral administration are intestinal membrane permability, size limitations, intestinal and hepatic metabolism and in some cases solubility limitations. Poor membrane permeabilities of hydrophilic peptides might be overcome by structurally modifying the compounds, thus increasing their membrane partition characteristics and/or their affinity to carrier proteins. Another approach is the site-specific delivery of the peptide to the most permeable parts of the intestine. The current view on size limitation for oral drug delivery has neglected partition considerations. Recent studies suggest that compounds with a molecular weight up to 4000 might be significantly absorbed, assuming appropriate partition behavior and stability. Metabolism, probably the most significant factor in the absorption fate of peptides, might be controlled by coadministration of competitive enzyme inhibitors, structural modifications and administration of the compound as a well absorbed prodrug that is converted into the therapeutically active agent after its absorption. For some peptides poor solubility might present a limitation to oral absorption, an issue that has been addressed by mechanistically defining and therefore improving formulation parameters. Effective oral peptide delivery requires further development in understanding these complex mechanisms in order to maximize the therapeutic potential of this class of compounds.

Keywords:  NASA Discipline Regulatory Physiology; Non-NASA Center

Mesh:

Substances:

Year:  1996        PMID: 11539926     DOI: 10.1016/0168-3659(95)00145-x

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  6 in total

1.  Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir.

Authors:  Jonathan M Miller; Arik Dahan; Deepak Gupta; Sheeba Varghese; Gordon L Amidon
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

Review 2.  Cell penetrating elastin-like polypeptides for therapeutic peptide delivery.

Authors:  Gene L Bidwell; Drazen Raucher
Journal:  Adv Drug Deliv Rev       Date:  2010-05-15       Impact factor: 15.470

3.  Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines.

Authors:  P Calvo; C Remuñan-López; J L Vila-Jato; M J Alonso
Journal:  Pharm Res       Date:  1997-10       Impact factor: 4.200

4.  A thermally targeted peptide inhibitor of symmetrical dimethylation inhibits cancer-cell proliferation.

Authors:  Gene L Bidwell; Angela A Whittom; Emily Thomas; Daniel Lyons; Michael D Hebert; Drazen Raucher
Journal:  Peptides       Date:  2010-02-16       Impact factor: 3.750

Review 5.  Understanding peroral absorption: regulatory aspects and contemporary approaches to tackling solubility and permeability hurdles.

Authors:  Prachi B Shekhawat; Varsha B Pokharkar
Journal:  Acta Pharm Sin B       Date:  2016-11-02       Impact factor: 11.413

6.  Thermally targeted delivery of a c-Myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model.

Authors:  Gene L Bidwell; Eddie Perkins; Joshua Hughes; Majid Khan; Judy R James; Drazen Raucher
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.